Immune responses to cancer: Are they potential biomarkers of prognosis?

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

B cell signature; Cancer; Immune system; Prognosis; T cell signature

Indexed keywords

B7 ANTIGEN; BIOLOGICAL MARKER; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEGINTERFERON ALPHA2B; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE;

APOPTOSIS; B LYMPHOCYTE; BREAST CARCINOMA; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; COLORECTAL CARCINOMA; EXOSOME; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; NEUTROPHIL; NONHUMAN; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84883228590     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00107     Document Type: Review

References (65)

1. Albers, A. E., Visus, C., Tsukishiro, T., Ferris, R. L., Gooding, W., Whiteside, T. L., et al. (2006). Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 12, 2394-2403.
2. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., et al. (2006). Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12, 465-472.
3. Bergmann, C., Strauss, L., Wieckowski, E., Czystowska, M., Albers, A., Wang, Y., et al. (2009). Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31, 371-380.
4. Biragyn, A., and Lee-Chang, C. (2012). A new paradigm for an old story: the role of regulatory B cells in cancer. Front. Immunol. 3:206. doi:10.3389/fimmu.2012.00206
5. Britten, C. M., Janetzki, S., Van Der Burg, S. H., Huber, C., Kalos, M., Levitsky, H. I., et al. (2011). Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol. Immunother. 60, 15-22.
6. Butterfield, L. H., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D., Wang, H. J., et al. (2003). Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9, 998-1008.
7. Butterfield, L. H., Palucka, A. K., Britten, C. M., Dhodapkar, M. V., Hakansson, L., Janetzki, S., et al. (2011a). Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin. Cancer Res. 17, 3064-3076.
8. Butterfield, L. H., Potter, D. M., and Kirkwood, J. M. (2011b). Multiplex serum biomarker assessments: technical and biostatistical issues. J. Transl. Med. 9, 173.
9. Camus, M., Tosolini, M., Mlecnik, B., Pages, F., Kirilovsky, A., Berger, A., et al. (2009). Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 69, 2685-2693.
10. Coronella, J. A., Spier, C., Welch, M., Trevor, K. T., Stopeck, A. T., Villar, H., et al. (2002). Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 169, 1829-1836.
11. Czystowska, M., Gooding, W. E., Szczepanski, M. J., Lopez-Abaitero, A., Ferris, R. L., Whiteside, T. L., et al. (2012). The immune signature of CD8+CCR7+ T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin. Cancer Res. 19, 889-899.
12. deLeeuw, R. J., Kost, S. E., Kakal, J. A., and Nelson, B. H. (2012). The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18, 3022-3029.
13. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J., and Rosenberg, S. A. (2003). Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342.
14. Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., and Brandau, S. (2012). Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61, 1155-1167.
15. Frey, A. B., and Monu, N. (2008). Signaling defects in anti-tumor T cells. Immunol. Rev. 222, 192-205.
16. Fridman, W. H., Galon, J., Pages, F., Tartour, E., Sautes-Fridman, C., and Kroemer, G. (2011). Prognostic and predictive impact of intra and peritumoral immune infiltrates. Cancer Res. 71, 5601-5605.
17. Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306.
18. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964.
19. Galon, J., Pages, F., Marincola, F. M., Thurin, M., Trinchieri, G., Fox, B. A., et al. (2012). The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1.
20. Greten, T. F., Manns, M. P., and Korangy, F. (2011). Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11, 802-807.
21. Guida, M., Casamassima, A., Monticelli, G., Quaranta, M., and Colucci, G. (2007). Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J. Transl. Med. 5, 51.
22. Hanash, S. M., Pitteri, S. J., and Faca, V. M. (2008). Mining the plasma proteome for cancer biomarkers. Nature 452, 571-579.
23. Hoffmann, T. K., Dworacki, G., Tsukihiro, T., Meidenbauer, N., Gooding, W., Johnson, J. T., et al. (2002). Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 8, 2553-2562.
24. Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., and Xiong, H. (2008). TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27, 218-224.
25. Iero, M., Valenti, R., Huber, V., Filipazzi, P., Parmiani, G., Fais, S., et al. (2008). Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 15, 80-88.
26. Kim, J. W., Ferris, R. L., and Whiteside, T. L. (2005a). Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin. Cancer Res. 11, 7901-7910.
27. Kim, J. W., Wieckowski, E., Taylor, D. D., Reichert, T. E., Watkins, S., and Whiteside, T. L. (2005b). Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 11, 1010-1020.
28. Kirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., et al. (2009). Immunogenicity and antitumor effects of vaccination with peptide vaccine±granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: eastern cooperative oncology group Phase II Trial E1696. Clin. Cancer Res. 15, 1443-1451.
29. Kotsakis, A., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A., and Whiteside, T. L. (2012). Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J. Immunol. Methods 381, 14-22.
30. Kuss, I., Hathaway, B., Ferris, R. L., Gooding, W., and Whiteside, T. L. (2005). Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv. Otorhinolaryngol. 62, 161-172.
31. Lanca, T., and Silva-Santos, B. (2012). The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology 1, 717-725.
32. Lippitz, B. E. (2013). Evidence for consistent cytokine pattern in cancer patients: a translational analysis. Lancet Oncol. 14, e218-e228.
33. Lucey, D. R., Clerici, M., and Shearer, G. M. (1996). Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9, 532-562.
34. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179.
35. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491-3494.
36. Nielsen, J. S., Sahota, R. A., Milne, K., Kost, S. E., Nesslinger, N. J., Watson, P. H., et al. (2012). CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 18, 3281-3292. doi:10.1186/1471-2407-9-292
37. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353, 2654-2666.
38. Pages, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautes-Fridman, C., and Fridman, W. H. (2010). Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102.
39. Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883-891.
40. Perisanidis, C., Kornek, G., Poschl, P. W., Holzinger, D., Pirklbauer, K., Schopper, C., et al. (2013). High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med. Oncol. 30, 334.
41. Potter, D. M., Butterfield, L. H., Divito, S. J., Sander, C. A., and Kirkwood, J. M. (2012). Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. J. Immunol. Methods 376, 108-112.
42. Pretscher, D., Distel, L. V., Grabenbauer, G. G., Wittlinger, M., Buettner, M., and Niedobitek, G. (2009). Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro-and hypo-pharyngeal carcinoma. BMC Cancer 9:292.
43. Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., et al. (2011). Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-oncology 13, 591-599.
44. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., et al. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186-192.
45. Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 102, 18538-18543.
46. Schaefer, C., Butterfield, L. H., Lee, S., Kim, G. G., Visus, C., Albers, A., et al. (2012). Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int. J. Cancer 131, 874-884.
47. Schafer, Z. T., and Brugge, J. S. (2007). IL-6 involvement in epithelial cancers. J. Clin. Invest. 117, 3660-3663.
48. Schmidt, M., Bohm, D., Von Torne, C., Steiner, E., Puhl, A., Pilch, H., et al. (2008). The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-5413.
49. Schmidt, M., Hellwig, B., Hammad, S., Othman, A., Lohr, M., Chen, Z., et al. (2012). A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin. Cancer Res. 18, 2695-2703.
50. Somasundaram, R., and Herlyn, M. (2012). Melanoma exosomes: messengers of metastasis. Nat. Med. 18, 853-854.
51. Szczepanski, M. J., Szajnik, M., Welsh, A., Whiteside, T. L., and Boyiadzis, M. (2011). Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 96, 1302-1309.
52. Tsukishiro, T., Donnenberg, A. D., and Whiteside, T. L. (2003). Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol. Immunother. 52, 599-607.
53. von Kleist, S., Berling, J., Bohle, W., and Wittekind, C. (1987). Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int. J. Cancer 40, 18-23.
54. Whiteside, T. L. (1993). Tumor Infiltrating Lymphocytes in Human Malignancies: Medical Intelligence Unit. Austin, TX: R. G. Landes, Co.
55. Whiteside, T. L. (2002). Cytokine assays. BioTechniques 10(Suppl. 4-8), 12-15.
56. Whiteside, T. L. (2005). Lymphocyte homeostasis and the antitumor immune response. Expert. Rev. Clin. Immunol. 1, 369-378.
57. Whiteside, T. L. (2006). The role of immune cells in the tumor microenvironment. Cancer Treat. Res. 130, 103-124.
58. Whiteside, T. L. (2008a). Immune monitoring of clinical trials with biotherapies. Adv. Clin. Chem. 45, 75-97.
59. Whiteside, T. L. (2008b). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912.
60. Whiteside, T. L. (2010). Immune responses to malignancies. J. Allergy Clin. Immunol. 125, S272-S283.
61. Whiteside, T. L. (2012). What are regulatory T cells (Treg) regulating in cancer and why? Semin. Cancer Biol. 22, 327-334.
62. Whiteside, T. L., and Ferrone, S. (2012). For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin. Cancer Res. 18, 2417-2419.
63. Whiteside, T. L., Mandapathil, M., Szczepanski, M., and Szajnik, M. (2011). Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull. Cancer 98, E25-E31.
64. Whiteside, T. L. (2013). Immune modulation of T cells and natural killer cells by tumor-derived exosomes. Biochem. Soc. Trans. 41, 245-251.
65. Yu, H., Kortylewski, M., and Pardoll, D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7, 41-51.